Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Eisai Inc.
Gradalis, Inc.
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
Children's Oncology Group
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Columbia University
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University of South Florida
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Sarcoma Alliance for Research through Collaboration